-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Denali Therapeutics Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2016 to 2023.
- Denali Therapeutics Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$117M, a 168% decline year-over-year.
- Denali Therapeutics Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$481M, a 195% decline year-over-year.
- Denali Therapeutics Inc. annual Operating Income (Loss) for 2023 was -$197M, a 42.3% increase from 2022.
- Denali Therapeutics Inc. annual Operating Income (Loss) for 2022 was -$341M, a 15.2% decline from 2021.
- Denali Therapeutics Inc. annual Operating Income (Loss) for 2021 was -$296M, a 572% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)